TGTX - TG Therapeutics

-

$undefined

N/A

(N/A)

TG Therapeutics NasdaqCM:TGTX TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Location: 3020 Carrington Mill Blvd., Morrisville, NC, 27560, United States | Website: https://www.tgtherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

4.989B

Cash

276.2M

Avg Qtr Burn

-15.26M

Short % of Float

17.11%

Insider Ownership

9.70%

Institutional Own.

63.17%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

TG-1801 (anti-CD47/anti-CD19) Details
B-cell malignancies, Cancer, B-cell lymphoma

Phase 1

Update

Phase 1

Update

TG-1701 (BTK inhibitor) Details
Chronic lymphocytic leukemia, Cancer

Phase 1

Update

Failed

Discontinued

Umbralisib (PI3K-delta & CK1-epsilon inhibitor) + Ublituximab (CD20) Details
R/R CLL (Relapsed/Refractory Chronic Lymphocytic Leukemia)

Failed

Discontinued